Prolonged alpha/beta interferon (IFN-alpha/beta) or recombinant IFN-beta treatment of RS485, NIH 3T3 cells transformed by a long terminal repeat-activated Ha-ras proto-oncogene resulted in revertants that maintain a non-transformed phenotype long after IFN treatment had been discontinued. Cloned persistent revertants (PRs) produced large amounts of the ras-encoded p21 and were refractile to transformation by EJras DNA and by transforming retroviruses which carried the v-Ha-ras, v-Ki-ras, v-abl, or v-fes oncogene. Transient treatment either in vitro or in vivo with cytidine analogs that alter gene expression by inhibiting DNA methylation resulted in transformation of PR, but not of NIH 3T3 cells. We wish to study the mechanisms involved in this persistent reversion. We hope to demonstrate altered patterns of gene expression in the persistent revertants by identifying in cDNA libraries cell messages that are differentially expressed in PRs and RS485s. The potential of these cDNAs to affect the phenotype of RS485 or persistent revertant cells will be evaluated by transfecting these cells with constructs that will allow the over-expression of either message or anti-sense message. Genomic clones of differentially expressed gene will also be obtained and the flanking regulatory regions analyzed. We also wish to investigate the possible roles of co-transforming oncogenes, endogenous IFN production, and DNA methylation of regulatory sites in the phenomenon of persistent reversion, and to study further the resistance of PRs to re-transformation by various viral and cellular oncogenes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA037351-04A1
Application #
3175179
Study Section
Pathology B Study Section (PTHB)
Project Start
1984-12-01
Project End
1993-05-31
Budget Start
1988-07-01
Budget End
1989-05-31
Support Year
4
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Henry M. Jackson Fdn for the Adv Mil/Med
Department
Type
DUNS #
City
Rockville
State
MD
Country
United States
Zip Code
20852
Contente, Sara; Attard, Frank A; Friedman, Robert M (2006) Identification of proteins immunologically related to interferon regulatory factor-1 that bind with interferon regulatory factor element. J Infect Dis 194 Suppl 1:S27-32
Contente, Sara; Attard, Frank A; Yeh, Tze-Jou Annie et al. (2003) Deregulated expression of interferon regulatory factor-1 in oncogene-transformed mouse fibroblasts. J Interferon Cytokine Res 23:639-47
Contente, S; Kenyon, K; Sriraman, P et al. (1999) Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene. Mol Cell Biochem 194:79-91
Friedman, R M; Yeh, A; Gutman, P et al. (1997) Reversion by deletion of transforming oncogene following interferon-beta and retinoic acid treatment. J Interferon Cytokine Res 17:647-51
Mello, M L; Contente, S; Vidal, B C et al. (1995) Modulation of ras transformation affecting chromatin supraorganization as assessed by image analysis. Exp Cell Res 220:374-82
Kenyon, K; Modi, W S; Contente, S et al. (1993) A novel human cDNA with a predicted protein similar to lysyl oxidase maps to chromosome 15q24-q25. J Biol Chem 268:18435-7
Contente, S; Csiszar, K; Kenyon, K et al. (1993) Structure of the mouse lysyl oxidase gene. Genomics 16:395-400
Mock, B A; Contente, S; Kenyon, K et al. (1992) The gene for lysyl oxidase maps to mouse chromosome 18. Genomics 14:822-3
Friedman, R M; Yeh, A; Tang, W (1992) Post-transcriptional regulation by interferon-alpha of epsilon-globin production in human erythroleukemia K-562 cells. J Interferon Res 12:311-6
Kenyon, K; Contente, S; Trackman, P C et al. (1991) Lysyl oxidase and rrg messenger RNA. Science 253:802

Showing the most recent 10 out of 15 publications